Levetiracetam
Levetiracetam is clinically used to treat a wide variety of seizure disorders, including partial, myoclonic, and tonic-clonic seizures as well as mood and psychiatric disorders such as anxiety, autism, and Tourette’s syndrome. Levetiracetam displays anticonvulsant/antiepileptic, neuromodulatory, anxiolytic, and cognition enhancing activities. Levetiracetam binds to synaptic vesicle glycoprotein SV2A, a membrane glycoprotein common to all synaptic and endocrine vesicles. SV2A plays a role in Ca2+-induced vesicle fusion, action potential proliferation, normal CNS function, and survival. Altering SV2A function inhibits presynaptic Ca2+ release, reduces excitatory postsynaptic potentials, and inhibits synaptic transmission. This compound is also under examination as a potential treatment for Alzheimer’s disease, as it reduces memory and learning deficits, synaptic dysfunction, and hippocampal remodeling in a transgenic murine model of the disease.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18939687
| Cas No. |
102767-28-2 |
|---|---|
| Purity |
≥98% |
| Formula |
C8H14N2O2 |
| Formula Wt. |
170.21 |
| Chemical Name |
2(S)-(2-oxopyrrolidin-1-yl)butyramide |
| IUPAC Name |
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide |
| Melting Point |
117°C |
| Solubility |
Soluble in DMSO, water, and ethanol, all to 34mg/mL |
| Appearance |
White to off white powder |
Vogl C, Mochida S, Wolff C, et al. The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway. Mol Pharmacol. 2012 Aug;82(2):199-208. PMID: 22554805.
Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimers disease model. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. PMID: 22869752.
Farooq MU, Bhatt A, Majid A, et al. Levetiracetam for managing neurologic and psychiatric disorders. Am J Health Syst Pharm. 2009 Mar 15;66(6):541-61. PMID: 19265183.
Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. PMID: 15210974.
